Ads
related to: monoclonal antibodies
Search results
NeuroSense taps PhaseV’s ML tech for Phase III ALS trial analysis
Clinical Trials Arena via Yahoo Finance· 6 days agoPhaseV will analyse NeuroSense’s Phase II ALS trial data, and results from these will inform Phase...
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
Zacks via Yahoo Finance· 4 days agoBristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy...
GSK to divest remaining 4.2% stake in Haleon
Pharmaceutical Technology via Yahoo Finance· 4 days agoThe agreement comprises an upfront payment of $1bn and $400m in regulatory milestone payments. Through the deal, GSK will gain access to AIO-001, a...
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building...
DJournalnow· 7 days agoThis represents another milestone in the Company's pursuit of a functional cure for HBV, following the Breakthrough Therapy Designation granted for BRII-179, a recombinant protein-based HBV ...
Sleep apnea is linked to changes in verbal memory
UC Irvine Today· 4 days agoUCI News highlighted a newly published study led by Bryce Mander, PhD, a UCI MIND faculty member and associate professor of psychiatry and human behavior, showing a link between sleep apnea ...
BioMarin cutting about 170 jobs after shuffling drug portfolio - San Francisco Business Times
The Business Journals· 6 days agoMost of the employees hit by the cuts were told Tuesday, the company (NASDAQ: BMRN) said. BioMarin...
Intel upgraded, Texas Instruments initiated: Wall Street's top analyst calls
The Fly via Yahoo Finance· 4 days agoH.C. Wainwright initiated coverage of Dianthus Therapeutics (DNTH) with a Buy rating and $40 price...
Jump Financial LLC Boosts Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT)
ETF DAILY NEWS· 4 days agoJump Financial LLC grew its holdings in Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 141.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities ...
Mount Sinai Awarded $6.6 Million From National Ins | Newswise
Newswise· 5 days agoNew York, NY – The Icahn School of Medicine at Mount Sinai Health System is spearheading a collaborative effort to investigate dupilumab as a treatment for children with alopecia areata, a disease ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 2 days agoAmgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive ...
